Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of January 5, 2025 • 7:00 PM ET

Date/Time Source News Release
11/13/2024 10:10 AM EST Newsfile Syros Stock - Investors of Syros Pharmaceuticals Encouraged to Contact Kehoe Law Firm, P.C. - SYRS
11/12/2024 04:30 PM EST Business Wire Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression
11/04/2024 11:00 AM EST ACCESSWIRE The Schall Law Firm Invites Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Related Infractions
11/03/2024 10:00 AM EST ACCESSWIRE Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm
11/02/2024 11:00 AM EDT ACCESSWIRE The Schall Law Firm Urges Investors To Join An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations
10/31/2024 11:00 AM EDT ACCESSWIRE Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Encouraged To Contact The Schall Law Firm
10/31/2024 07:30 AM EDT Business Wire Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update
10/30/2024 11:00 AM EDT ACCESSWIRE The Schall Law Firm Urges Investor Participation In An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations
10/29/2024 11:00 AM EDT ACCESSWIRE Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Shareholders Are Encouraged To Contact The Schall Law Firm
10/28/2024 11:00 AM EDT ACCESSWIRE The Schall Law Firm Urges Investor Participation In An Inquiry Into Syros Pharmaceuticals, Inc. For Securities Law Violations
Page